Skip to main content
Article
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Annals of Oncology (2020)
  • A. Algazi, University of California, San Francisco
  • S. Bhatia, University of Washington
  • S. Agarwala, St. Luke's Cancer Center, Bethlehem, USA
  • M. Molina, Lakeland Health
  • K. Lewis, University of Colorado Boulder
  • M. Faries, Providence John Wayne Cancer Institute, Santa Monica, USA
  • L. Fong, University of California, San Francisco
  • L.P. Levine, University of California, San Francisco
  • M. Franco, University of California, San Francisco
  • A. Oglesby, University of California, San Francisco
  • C. Ballesteros-Merino, Providence Portland Medical Center
  • C.B. Bifulco, Providence Portland Medical Center
  • B.A. Fox, Providence Portland Medical Center
  • D. Bannavong, OncoSec Medical Incorporated, San Diego, USA
  • R. Talia, OncoSec Medical Incorporated, San Diego, USA
  • E. Browning, OncoSec Medical Incorporated, San Diego, USA
  • M.H. Le, OncoSec Medical Incorporated, San Diego, USA
  • R.H. Pierce, OncoSec Medical Incorporated, San Diego, USA
  • S. Gargosky, OncoSec Medical Incorporated, San Diego, USA
  • K.K. Tsai, University of California, San Francisco
  • C. Twitty, OncoSec Medical Incorporated, San Diego, USA
  • A.I. Daud, University of California, San Francisco
Publication Date
April 1, 2020
DOI
10.1016/J.ANNONC.2019.12.008
Citation Information
A. Algazi, S. Bhatia, S. Agarwala, M. Molina, et al.. "Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients." Annals of Oncology Vol. 31 Iss. 4 (2020) p. 532 - 540
Available at: http://works.bepress.com/carlo-bifulco/52/